Elbit Imaging Ltd (EMITF)

[midastouch017]

Elbit Imaging Ltd. Announces That Gamida Cell's Has Made First Patient Transplanted in Phase 3 Registration Study of Nicord for Blood Cancers

TEL AVIV, ISRAEL / ACCESSWIRE / February 28, 2017 / Elbit Imaging Ltd. (EMITF) (EMITF) ("Elbit" or the "Company") announced today, in further to its announcement dated December 12, 2016, that it was informed by Gamida Cell Ltd. ("Gamida"), an indirect associate of the Company, that the first patient has been transplanted in Gamida's Phase 3 study of NiCord®, in development as a cure for patients with blood cancer (the "Trial".)

The Trial is an international, randomized, controlled, open-label, multicenter, registration study. The trial is expected to enroll 120 patients, ages 16-60 that will be enrolled in medical centers in the U.S and Europe. The Trial will evaluate the safety and efficacy of transplanting NiCord® as compared to transplanting un-manipulated cord blood in patients with hematological malignancies (blood cancers). The primary end point is the time estimation to neutrophil engraftment.

As of today, the development of NiCord remains at the clinical stage of development.

Gamida develops cellular and immune therapies for the treatment of cancer and orphan genetic diseases. Gamida's pipeline of products are in development to treat a wide range of conditions, including blood cancer, lymph nodes cancer and genetic hematological diseases such as sickle cell disease and thalassemia.

The Company holds approximately 89.9% of the share capital of Elbit Medical Technologies Ltd. (TASE:EMTC) (85.6% on a fully diluted basis) which, in turn, holds approximately 25% of the share capital in Gamida (22.5% on a fully diluted basis).